Key Insights Alvotech's significant private equity firms ownership suggests that the key decisions are influenced ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

Has Alvotech (ALVO) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

Alvotech (NASDAQ:ALVO – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $12.41, but opened at $12.80. Alvotech shares last traded at $12.87, with a ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

In trading on Wednesday, shares of Alvotech (Symbol: ALVO) crossed below their 200 day moving average of $12.51, changing hands as low as $12.43 per share. Alvotech shares are currently trading ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...